Skip to main content
Infant Bacterial Therapeutics logo

Infant Bacterial Therapeutics — Investor Relations & Filings

Ticker · IBT ISIN · SE0008015259 LEI · 2138008KVBXCRJGP6Z26 ST Manufacturing
Open in API
Filings indexed 212 across all filing types
Latest filing 2021-05-04 Interim / Quarterly Rep…
Country SE Sweden
Listing ST IBT

About Infant Bacterial Therapeutics

https://ibtherapeutics.com/

Infant Bacterial Therapeutics (IBT) is a pharmaceutical company that develops drugs influencing the human infant microbiome to prevent or treat rare diseases. The company's primary focus is on premature infants, addressing urgent medical needs such as necrotizing enterocolitis (NEC), a potentially lethal inflammatory bowel disorder. Its lead drug candidate, IBP-9414, is a New Biological Entity (NBE) currently in a Phase 3 clinical study. IBT also aims to develop treatments for diseases caused by antibiotic-resistant bacteria. The company is developing its medicines for approval by regulatory agencies, including the FDA and EMA.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Management Statement, January 1 – March 31, 2021' and 'Interim report January 1-March 31, 2021'. It contains substantive financial data, including a table of 'Selected financial data' for the period, and detailed management commentary on business operations, clinical trials, and significant events. It is a comprehensive quarterly financial report, not merely an announcement or a press release summary. Q1 2021
2021-05-04 English
Infant Bacterial Therapeutics expands The Connection Study to include infants with a birth weight below 750 grams
Regulatory Filings Classification · 95% confidence The document is a 'Press Release' dated April 29, 2021, announcing an update regarding the expansion of enrollment criteria for a clinical study ('The Connection Study'). It details a decision made by the Data Monitoring Committee (DMC) and includes commentary from the CEO. This type of announcement, which communicates a specific operational or clinical development update outside of standard periodic financial reports (like 10-K or IR), fits best under the general category for regulatory announcements or news releases that don't match other specific codes. Since it is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a specific legal/insider filing, the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for significant, non-standard corporate news releases that must be made public under regulations like the EU Market Abuse Regulation (explicitly mentioned at the end). The document length (3186 chars) is short, but it is the primary announcement itself, not just an announcement *of* another report.
2021-04-29 English
Infant Bacterial Therapeutics utökar The Connection Study och inkluderar spädbarn med en födelsevikt under 750 gram
Regulatory Filings Classification · 95% confidence The document is a press release written in Swedish announcing an update regarding a clinical trial ('The Connection Study') for Infant Bacterial Therapeutics AB. Specifically, it details the expansion of patient inclusion criteria based on a safety review by the Data Monitoring Committee (DMC). This type of announcement, which communicates operational updates, clinical trial progress, and management commentary outside of standard periodic financial reports (like 10-K or IR), typically falls under general regulatory announcements or investor relations communications. Since it is not a formal financial report (10-K, IR, ER), a specific management discussion (MDA), or a capital event (CAP, SHA), the most appropriate general category for a significant, non-financial operational update that must be publicly disclosed (as indicated by the final paragraph referencing EU market abuse regulation) is Regulatory Filings (RNS). The document length is short (3334 chars), but it is the primary content itself, not an announcement *about* another report, thus RPA is less suitable than RNS for this type of operational news release.
2021-04-29 Swedish
Infant Bacterial Therapeutics receives additional patent protection in China
Regulatory Filings Classification · 88% confidence The document is a 'Press Release' dated April 15, 2021, announcing that Infant Bacterial Therapeutics AB (IBT) received a patent grant in China for its drug candidate IBP-9414. This announcement concerns intellectual property protection, which is a specific corporate event. It is not a comprehensive annual report (10-K), an interim report (IR), an earnings release (ER), or a management discussion (MDA). It is a specific announcement regarding intellectual property/patents. Among the provided codes, none perfectly match 'Patent Grant Announcement'. However, the closest relevant categories are those dealing with corporate actions or specific regulatory/legal updates. Since it is an announcement about intellectual property protection, it is most closely related to legal/regulatory matters or general corporate news. Given the options, 'LTR' (Legal Proceedings Report) is too narrow (it's about gaining protection, not litigation), and 'RNS' (Regulatory Filings) is the general fallback. Since this is a specific, material corporate announcement that doesn't fit the primary financial reports or management changes, 'RNS' (Regulatory Filings/General Announcement) is the most appropriate fallback classification for a press release detailing a specific corporate event like a patent grant, especially since there is no specific 'IP Grant' code. The document length is short (3159 chars) and it is a press release, not a full regulatory filing itself, but it is a formal announcement of a material event.
2021-04-15 English
Infant Bacterial Therapeutics erhåller ytterligare patentskydd i Kina
Regulatory Filings Classification · 95% confidence The document is titled "Pressmeddelande" (Press Release) and dated April 15, 2021. It announces that Infant Bacterial Therapeutics AB (IBT) has received patent approval in China for a formulation related to their drug candidate IBP-9414. The text details intellectual property protection and does not contain comprehensive financial statements (like 10-K or IR), management compensation (DEF 14A), or voting results (DVA). It is a specific announcement regarding legal/IP status. While it relates to intellectual property, it is not a formal Legal Proceedings Report (LTR) about a lawsuit, but rather a positive update on patent protection. Since it is a specific regulatory announcement that doesn't fit perfectly into the core financial reports, and it is a formal communication to the market, it falls best under the general 'Regulatory Filings' category (RNS) as a miscellaneous regulatory announcement, or potentially 'IP' (Intellectual Property). Given the context of corporate filings, RNS serves as the best general regulatory announcement fallback for non-financial, non-management specific news like patent grants. However, since 'IP' (Intellectual Property) is not explicitly defined but the content is purely about patent grants, and RNS is defined as 'General regulatory announcements and fallback category for miscellaneous filings that do not neatly fit into other specific categories', RNS is the most appropriate general classification for this type of press release announcement.
2021-04-15 Swedish
Annual Report (ESEF) 2021
Annual Report (ESEF)
2021-04-09 Swedish

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.